Sarepta Therapeutics (SRPT) Shorts Squeezed After Eteplirsen Receives FDA Approval

September 19, 2016 11:27 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Sarepta Therapeutics (NASDAQ: SRPT) shorts were pressured after the FDA approved its DMD drug eteplirsen. The news sent shares up over 90% intraday and caught many shorts sellers off guard. According to Nasdaq data from August 31st, short interest was 14.8 million shares, or 33% of the float. Days to cover was 8.3 on average volume of 1.8 million shares.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Short Sales, Trader Talk

Add Your Comment